Related Experiment Video

Updated: Aug 11, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis

Andrew J K Ostör1, Edwin R Chilvers, Margaret F Somerville

  • 1Rheumatology Department, Addenbrooke's Hospital, Cambridge, UK. andrew.ostor@addenbrookes.nhs.uk

The Journal of Rheumatology
|March 3, 2006
PubMed

Insights

Patients with rheumatoid arthritis (RA) developing lung issues after infliximab therapy need caution. This is especially true for those with existing usual interstitial pneumonia, suggesting risks with anti-tumor necrosis factor-alpha treatments.

Area of Science:

  • Rheumatology
  • Pulmonology
  • Immunology

Background:

  • Rheumatoid arthritis (RA) is a chronic autoimmune disease.
  • Infliximab is a biologic therapy targeting tumor necrosis factor-alpha (TNF-α).
  • Pulmonary complications are a known, though not fully understood, risk associated with TNF-α inhibitors.

Observation:

  • Five patients with RA experienced pulmonary complications after receiving infliximab.
  • Four of these patients had pre-existing usual interstitial pneumonia (UIP).
  • The exact mechanism causing lung injury from infliximab remains unclear.

Findings:

  • Infliximab therapy was associated with new or worsening pulmonary issues in RA patients.
  • Patients with underlying UIP appear to be at higher risk for these complications.
  • The severity of lung disease may influence treatment decisions.

Implications:

  • Caution is advised when using anti-TNF-α therapies like infliximab in RA patients with significant lung disease.
  • Consideration of alternative treatments may be necessary for RA patients with severe pulmonary conditions.
  • Further research into the pathophysiology of infliximab-induced lung injury is warranted.

More Related Videos

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Asthma-III: Symptoms and Complications01:24

Asthma-III: Symptoms and Complications

Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...